These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7963690)

  • 21. Ribozymes in gene therapy.
    Thompson JD; Macejak D; Couture L; Stinchcomb DT
    Nat Med; 1995 Mar; 1(3):277-8. PubMed ID: 7585047
    [No Abstract]   [Full Text] [Related]  

  • 22. Ribozyme- and deoxyribozyme-strategies for medical applications.
    Schubert S; Kurreck J
    Curr Drug Targets; 2004 Nov; 5(8):667-81. PubMed ID: 15578948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hammerhead ribozymes for target validation.
    Goodchild J
    Expert Opin Ther Targets; 2002 Apr; 6(2):235-47. PubMed ID: 12223083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The application of ribozymes to HIV infection.
    Rossi JJ
    Curr Opin Mol Ther; 1999 Jun; 1(3):316-22. PubMed ID: 11713796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ribozymes: from mechanistic studies to applications in vivo.
    Ohkawa J; Koguma T; Kohda T; Taira K
    J Biochem; 1995 Aug; 118(2):251-8. PubMed ID: 8543555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ribozymes: recent advances in the development of RNA tools.
    Puerta-Fernández E; Romero-López C; Barroso-delJesus A; Berzal-Herranz A
    FEMS Microbiol Rev; 2003 Apr; 27(1):75-97. PubMed ID: 12697343
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA hairpin loops repress protein synthesis more strongly than hammerhead ribozymes.
    Drew HR; Lewy D; Conaty J; Rand KN; Hendry P; Lockett T
    Eur J Biochem; 1999 Nov; 266(1):260-73. PubMed ID: 10542074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribozyme: a clinical tool.
    Khan AU
    Clin Chim Acta; 2006 May; 367(1-2):20-7. PubMed ID: 16426595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural similarities between hammerhead ribozymes and the spliceosomal RNAs could be responsible for lack of ribozyme cleavage in yeast.
    Castanotto D; Li H; Chow W; Rossi JJ; Deshler JO
    Antisense Nucleic Acid Drug Dev; 1998 Feb; 8(1):1-13. PubMed ID: 9512091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential use of catalytic RNAs in therapy of HIV infection and other diseases.
    Rossi JJ; Cantin EM; Sarver N; Chang PF
    Pharmacol Ther; 1991; 50(2):245-54. PubMed ID: 1763136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. DNA-RNA chimeric hammerhead ribozyme to transforming growth factor-beta(1) mRNA inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats.
    Teng J; Fukuda N; Hu WY; Nakayama M; Kishioka H; Kanmatsuse K
    Cardiovasc Res; 2000 Oct; 48(1):138-47. PubMed ID: 11033116
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential activity of trans-acting hammerhead ribozymes targeted to beta amyloid peptide precursor mRNA by altering the symmetry of helices I and III.
    Denman RB; Smedman M; Kung L
    Arch Biochem Biophys; 1995 Oct; 323(1):71-8. PubMed ID: 7487076
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drugs made of RNA: development and application of engineered RNAs for gene therapy.
    Drude I; Dombos V; Vauléon S; Müller S
    Mini Rev Med Chem; 2007 Sep; 7(9):912-31. PubMed ID: 17897081
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clone, expression and cleavage activity of anti-caspase-7 hammerhead ribozyme in vitro].
    Zhang W; Xie Q; Zhou XQ; Jiang S; Jin YX
    Zhonghua Gan Zang Bing Za Zhi; 2004 Nov; 12(11):684-7. PubMed ID: 15623380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purging of chronic myelogenous leukemia cells by retrovirally expressed anti-bcr-abl ribozymes with specific cellular compartmentalization.
    Mendoza-Maldonado R; Zentilin L; Fanin R; Giacca M
    Cancer Gene Ther; 2002 Jan; 9(1):71-86. PubMed ID: 11916246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of ribozymes that target stathmin, a major regulator of the mitotic spindle.
    Mistry SJ; Benham CJ; Atweh GF
    Antisense Nucleic Acid Drug Dev; 2001 Feb; 11(1):41-9. PubMed ID: 11258620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.